Table 1.

Biological and cytogenetic-molecular characteristics of blasts from diagnostic patients with AML

Patient ID	Diagnostic	Cytogenetics	Molecular	Age (years)	Gender	Blasts (%)	Cd123 (%)	Use
14 085	AML	46, XY	NPM1+, FLT3-ITD	42	M	87	80	AG density
14 176	AML-M1	46, XX	Normal	44	F	83	75	AG density ELISA
14 093	AML-M4	46, XX	NPM1MUT, FLT3-ITD	52	F	81	86	AG density
14 184	AML-M1	46, XX, t(8;21)	AML1-ETO	14	F	90	84	AG density
14 268	AML	46, XY, inv(16)	NPM1MUT, FLT3-ITD	69	M	95	92	AG density Autologous
14 269	AML-M5	47, XX,+8	Normal	64	F	92	90	AG density ELISA
14 266	AML	46, XX, t(8;21)	AML1-ETO, FLT3-ITD+	48	F	90	92	AG density ELISA
14 123	AML	46, XY, t(3;3)	Normal	28	M	42	77	AG density
14 185	AML	46, XY, inv(16)	Normal	8	M	77	72	AG density
14 143	AML-M1	46, XY	Normal	43	M	90	90	AG density
14 156	AML	46, XY,11q23	MLL-AF6	1	M	88	100	AG density
14 144	AML	46, XY, del(7)(q22)	Normal	61	M	88	98	AG density
14 141	AML-M5	46, XX, t(8;21)	AML1-ETO	39	F	83	82	AG density
14 091	AML-M4	47, XX,+8	Normal	61	F	95	80	AG density
14 272	AML	46, XX	NPM1MUT, FLT3-ITD	44	F	73	88	Autologous
14 274	AML	46, XX, t(8;21)	AML1-ETO	13	F	85	75	Autologous
ABT3974	AML	46, XY,+9, inv(16)(p13;q22), der(17)t(11;17)(q13;q25)	CEBPA, FLT3-TKD, WT1	37	M	91	87	AG density
ABT5270	AML	46, XY	NPM1, DNMT3A, IDH1	55	M	74	77	AG density
ABT4435	AML	46, XX	IDH2, DNMT3A	70	F	24	96	AG density
ABT8326	sAML	44–45X-, Y, der(3), del(7)(q22), der(8), add(12)(p13),−18, add(21)(q28)	TET2, CALR	61	M	6	56	AG density
ABT7693	AML	46, XY	NPM1, IDH1, PTPN11	45	M	80	99	AG density
ABT4470	AML	47, XX	NPM1, IDH1, BCOR	72	F	71	76	AG density
ABT5718	AML	46, XX	CEBPAbi, DNMT3A, TET2	52	F	34	65	AG density
ABT8597	AML	NA	NPM1, IDH1, NRAS	69	F	71	100	AG density
ABT3906	AML	NA	NPM1, FLT3-ITDHIGH, IDH1	40	M	93	77	AG density
ABT4685	tAML	46, XX	CEBPAbi, TET2, WT1	67	F	49	93	AG density

AG, antigen; AML, acute myeloid leukemia; F, female; M, male; sAML, secondary acute myeloid leukemia; tAML, therapy-related acute myeloid leukemia.